Breast Cancer

Early trial shows botanical for advanced breast cancer ready for next step.

ColoPrint gene assay can help guide treatment options for some colorectal patients, study shows.

The latest in cancer prevention, diagnosis and treatment.

Patients and the FDA battle over Avastin's breast cancer indication.

Understanding breast cancer biology provides some new targets.

A review of the fifth and latest version of Dr. Susan Love's Breast Book.

Connecticut and New York enact laws that require physicians to better communicate breast health information.

New directions in surgery, treatment and reconstruction are changing breast cancer.

Sentinel node biopsy reduces complications of breast surgery.

One of the primary goals of sentinel node biopsy is to reduce the need for axillary dissection to minimize a woman’s chance of getting lymphedema, a chronic buildup of fluid that occurs as a result of the body’s impaired ability to drain lymph fluid from tissue.

Radiation techniques have been refined and shortened for women who qualify.

The controversy over the use of accelerated partial-breast radiation (APBI) is reflected in the recommendations from the professional organizations that oversee radiation oncology and surgery.

Knowing the cellular basics drives treatment decisions.

Surgeons disagree on whether nipple-sparing surgery has benefits.

Things to know before deciding on a nipple-sparing mastectomy.

News and perspectives from the breast cancer community.

Widespread genetic testing of Lynch syndrome is cost-efficient and reduces the risk of colorectal cancer.

Updates from the annual meetings of the American Society of Hematology and the San Antonio Breast Cancer Symposium.

Studies conflict on bone-building drug's ability to prevent recurrence.

In recent years, scientists discovered that an enzyme called CYP2D6 could possibly predict whether a patient would respond to the drug. Small studies aimed at confirming the predictive link, however, have been consistently inconsistent.

Adding Afinitor, an mTOR inhibitor, to tamoxifen helped women with metastatic breast cancer live about four months longer without their disease getting worse, according to a study presented Thursday at SABCS.

After a diagnosis of stage 3 breast cancer at age 32, Moana Papa embraced advocacy, traveling from her home in New Zealand to the San Antonio Breast Cancer Symposium to bring information back to her community.

Obese women with breast cancer are at higher risk for recurrence and death, but new findings suggest it may depend on cancer subtype.

In the NeoSphere study, various combinations of a new HER2-targeted agent called pertuzumab, Herceptin and chemothery were studied in early-stage breast cancer patients with encouraging results.

After breast cancer, clinical sexologist Sueann Mark, PhD, developed a program to help survivors regain their sexuality after cancer.

New studies start to pinpoint the best strategy for treating HER2-positive breast cancer before surgery and lay the groundwork for future clinical trials.

Two studies presented at SABCS offer a better understanding of what to do with the information sentinel lymph nodes provide.

When faced with breast cancer as a young Jewish woman, Rochelle Shoretz learned that her heritage, including its risk of cancer-associated mutations, brought up unique issues, which led her to create Sharsheret, a nonprofit organization.

Findings from the long-awaited AZURE trial show Zometa may prevent recurrence, but not for everyone.